ОСОБЕННОСТИ РАЗВИТИЯ ПРЕЭКЛАМПСИИ ПРИ ЭКО-ИНДУЦИРОВАННОЙ БЕРЕМЕННОСТИ: ОБЗОР ЛИТЕРАТУРЫ
2024 жыл | Шығарылым: 3 | Беттер: 175-185
ЭРОЗИВНЫЙ ЭЗОФАГИТ У ДЕТЕЙ ШКОЛЬНОГО ВОЗРАСТА (ПЯТИЛЕТНИЙ ПЕРИОД НАБЛЮДЕНИЯ)
2024 жыл | Шығарылым: 3 | Беттер: 54-62
РАСПРОСТРАНЁННОСТЬ И ФАКТОРЫ РИСКА ГЕСТАЦИОННОГО САХАРНОГО ДИАБЕТА
2024 жыл | Шығарылым: 3 | Беттер: 164-174
ИММУНОЛОГИЧЕСКИЙ И ЦИТОГЕНЕТИЧЕСКИЙ СТАТУС ОТНОСИТЕЛЬНО ЗДОРОВЫХ ЖИТЕЛЕЙ Г. АЛМАТЫ И АЛМАТИНСКОЙ ОБЛАСТИ В ДИНАМИКЕ
2024 жыл | Шығарылым: 3 | Беттер: 40-53
THE FREQUENCY AND EFFICACY ASSESSMENT OF RADIOIODINE THERAPY FOR DISTANT METASTASES OF THYROID CANCER
2025 жыл | Шығарылым: 2 | Беттер: 39-45
АССОЦИАЦИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ С ПОЛИМОРФИЗМОМ ТРАНСПОРТНОГО БЕЛКА У МУЖЧИН СТАРШЕГО ВОЗРАСТА КАЗАХСКОГО ЭТНОСА
2025 жыл | Шығарылым: 2 | Беттер: 46-52
CURRENT STATUS AND ACHIEVEMENTS OF EXTRACORPOREAL HEMOCORRECTION IN KAZAKHSTAN: RECENT ACHIEVEMENTS AND CURRENT CHALLENGES
2025 жыл | Шығарылым: 2 | Беттер: 53-61
CLINICAL SIGNIFICANCE OF SERUM KLOTHO LEVELS IN PATIENTS WITH STEMI AND RENAL DYSFUNCTION
2025 жыл | Шығарылым: 2 | Беттер: 62-69
ANTIBIOTIC RESISTANCE OF STAPHYLOCOCCUS AUREUS TO VARIOUS CLINICAL BIOMATERIALS: A COMPARATIVE ANALYSIS
2025 жыл | Шығарылым: 2 | Беттер: 70-77
USING OF ATORIS AT FEMALES WITH ARTERIAL HYPERTENSION AND HYPERLIPIDEMIA
So, medicine Atoris is may be used as high effective lipid lowering drug for secondary prophylaxis of cardiovascular compli-cations at females with high risk of ischemic heart disease.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 40-42
ARTERIAL HYPERTENSION AT OLD AGE PATIENTS
Problem of arterial hypertension at old age patients is connected with it’s wide spreading and tendency to aging of popu-lation. In old age there are different risk factors and accompanying diseases, which permit to say about that group of patients are in high or very high risk of cardiovascular complications not depending on degree of increasing of blood pressure.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 38-40
DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (CHF)
This lecture consist of actuality, definition, main etiological factors of chronic heart failure and diagnostic criteria. And there is medicamentous therapy and principles of surgical and electrophysiological methods of treatment of CHF in this lecture.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 32-37
CALCIUM CHANNELS BLOCKERS - A ROLE IN MODERN THERAPY OF CARDIOVASCULAR DISEASES: IN FOCUS – DILTIAZEM
Calcium channels blockers – group of the drugs which basic property is ability to brake a calcium current inside of smooth muscle cells through the special channels named “slow calcium channels”. Diltiazem Lannacher renders cardioprotective action with antioxidative effect, angioprotective action, antiagregant action, antiatherogenous action, nephroprotective action, cerebroprotective action.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 24-34
DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AT TREATMENT OF ARTERIAL HYPERTENSION: LERKAMEN
Arterial hypertension (AH) is independent risk factor of myocardial infarction, brain stroke, chronic heart failure (CHF) and hypertensive nephropathy, death from cardiovascular diseases.
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
Main aim of therapy of AH is maximal decreasing of risk of development of cardiovascular morbidity and mortality.
This lecture includes data about pharmacodynamics and therapeutic efficiency of dihydropyridine calcium channel blocker Lerkamen, its advantages, indications and contraindications, metabolic neutrality, organ protection.
Толығырақ
2012 жыл | Шығарылым: 2 | Беттер: 18-24